Stocks Health care ASND

NASDAQ · Health care

Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S reported revenue of €720.1M in fiscal 2025, up 98.0% from a year earlier. It posted a net loss of €228M. At December 31, 2025 it held €616M in cash against €720.3M of debt.

Watch ASND in 60 seconds

Follow ASND

Free, no password. An email when ASND files with the SEC.

Key facts about Ascendis Pharma A/S

Net worth

Ascendis Pharma A/S has a market value (market cap) of $15.9B at the latest share price, and shareholders' equity of -€162.8M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2025 revenue was €720.1M (+98.0% year on year), with a net loss of €228M.

Cash flow

In fiscal 2025 operations brought in €53.9M of cash.

What Ascendis Pharma A/S does

Ascendis Pharma A/S is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ASND.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in EUR.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where ASND ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Ascendis Pharma A/S has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. November 6, 2026
   Foreign issuer update 6-K
2. November 5, 2026
   Passive stake changed SCHEDULE 13G/A
3. October 26, 2026
   Foreign issuer update 6-K
4. October 16, 2026
   Foreign issuer update 6-K
5. October 14, 2026
   Foreign issuer update 6-K
6. September 29, 2026
   Foreign issuer update 6-K
7. September 15, 2026
   Foreign issuer update 6-K
8. September 15, 2026
   Foreign issuer update 6-K
9. September 9, 2026
   Foreign issuer update 6-K
10. September 9, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 28, 2026. Insider transactions on SEC

Insider trades

What the people running Ascendis Pharma A/S did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $492.7K and sold $872.9K worth of shares in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ASND

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Artisan Partners Asset Management Inc. 4.2% (August 13, 2026); Capital International Investors 3.2% (May 14, 2026).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 311 managers reported a position.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

3 insiders reported holding 11,267 shares in total, about $2.9M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ASND

What does Ascendis Pharma A/S do?

Ascendis Pharma A/S is a company in the Health care sector, listed on NASDAQ as ASND. Its shares trade on NASDAQ under the ticker ASND.

What is Ascendis Pharma A/S's net worth?

Ascendis Pharma A/S has a market value (market cap) of $15.9B at the latest share price, and shareholders' equity of -€162.8M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Ascendis Pharma A/S profitable?

No. In fiscal 2025 it reported a net loss of €228M on revenue of €720.1M.

How much revenue does Ascendis Pharma A/S make?

In fiscal 2025 Ascendis Pharma A/S reported revenue of €720.1M. That is 98.0% more than a year earlier.

When did Ascendis Pharma A/S last report?

Its newest filing of any kind is the foreign issuer update from November 6, 2026.

Similar companies

Compare ASND with

Compare ASND with any company

Follow ASND

Get an email when Ascendis Pharma A/S files with the SEC: results, executive changes, material agreements and annual reports.

Follow ASND

Free, no password. An email when ASND files with the SEC.

Where the numbers come from

Financial figures are the values Ascendis Pharma A/S tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.